September 23, 2019

FDA: Class I recall of Allergan Natrelle Biocell textured breast implants

By: Judy Mathias

Editor's Note

The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.

The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.

Distribution dates are September 14, 2014, to July 24, 2019.


Join our community

Learn More
Video Spotlight
Live chat by BoldChat